Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 8,137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 17,418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 56
States / cities: Tucson, Arizona • Anaheim, California • Canoga Park, California + 46 more

Conditions: Healthy Volunteers
Interventions: Glasdegib, Rifampin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stroke
Interventions: Moderate-Intensity Locomotor Training Program, High-Intensity Locomotor Training Program, High-Step Count Locomotor Training Program; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 95 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Tolperisone Hydrochloride, Cyclobenzaprine Hydrochloride 10 MG, Placebo; Drug · Other
Lead sponsor: Neurana Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Long Beach, California • Berlin, New Jersey

Conditions: Psoriasis
Interventions: Placebo, 50 mg etanercept, 80 mg ixekizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 41
States / cities: Anaheim, California • Bakersfield, California • Bell Gardens, California + 38 more

Conditions: Breast Cancer
Interventions: Gene Modified T Cells, Gene Modified T Cells and Interleukin 2; Biological
Lead sponsor: Roger Williams Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Niemann-Pick Disease, Type C
Interventions: IB1001; Drug
Lead sponsor: IntraBio Inc; Industry
Eligibility: 6 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bioavailability of ASP015K, Healthy Subjects, Pharmacokinetics of ASP015K, Food Effect of ASP015K
Interventions: ASP015K; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Type 2 Diabetes
Interventions: G4H-Diab-Nano; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 12 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mild Cognitive Impairment (MCI)
Interventions: Tadalafil 5 mg; Drug
Lead sponsor: Los Angeles Brain Science Project; Other
Eligibility: 60 Years to 90 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Interventions: DuoCAR20.19.22-D95, Fludarabine (Conditional therapy), Cyclophosphamide (Conditional therapy); Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 1
States / cities: Westwood, Kansas

Conditions: Tourette Syndrome
Interventions: TEV-50717, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 33
States / cities: Dothan, Alabama • Rogers, Arkansas • Anaheim, California + 27 more

Conditions: Infections, Bacterial
Interventions: Gepotidacin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Tobacco Use Disorder
Interventions: Tolcapone, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Physical Disability
Interventions: EnhanceWellness for Disability (EW-D), Wellness Education; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 45 Years to 64 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancers - Throat
Interventions: Chemoradiation, Pamiparib, Hydroxyurea, Fluorouracil (5FU), Tislelizumab; Radiation · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: Fedratinib, Digoxin, Rosuvastatin, Metformin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Metformin 500 mg q12h, Dolutegravir 50 mg q24h, Dolutegravir 50 mg q12h; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Relapsed or Refractory Lymphoma
Interventions: Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg, Rabeprazole 40 mg; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Sclerosis
Interventions: Truvada (tenofovir/emtricitabine); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Medication Adherence, Asthma in Children
Interventions: Nominal Financial Incentives, Daily Adherence Reminders/Adherence Performance Feedback; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 12 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
Interventions: Rapidly generated virus specific T (R-MVST) cells; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Prevention
Interventions: Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen; Drug · Radiation
Lead sponsor: Ian McGowan; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

Optimal Dosing of High-Intensity Locomotor Training for Step Attainment and Locomotor Outcomes in Stroke Patients Undergoing Acute Inpatient Rehabilitation

Effects of Tolperisone on Measures of Drowsiness and Cognitive Function

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer

N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)

A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects

Video Games for Obesity and Diabetes Prevention-Diab & Nano

Effects of Tadalafil on Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitive Impairment

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects

Neural Substrates in Nicotine Withdrawal

A Community Wellness Program for Adults Living With Long-term Physical Disability

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial

R-MVST Cells for Treatment of Viral Infections

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations